Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

CardioCell

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

- PMLiVE

Astellas launches cancer challenge social media campaign

Teamsup with USA Rugby and the Australian Rugby Union for #pass4prostate

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

- PMLiVE

Shire adds Sara Mathew to board of directors

Comes as firm aims to become global biotechnology leader

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

- PMLiVE

Bringing about digital health change

Qualcomm's Rick Valencia on what the future could hold

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

mRNA – message received

Assessing the growing pharma interest in modified messenger RNA

- PMLiVE

EM Imaging appoints new chairman

John Jeans to bring firm to forefront of molecular imaging market

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links